700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Commentary Open Access
Multiple myeloma (MM) is a clonal plasma cell neoplasm that utilizes bone marrow microenvironment for survival and proliferation [1-3]. However, current therapies could rarely cure MM. The relapse or refractory aspect of the disease is commonly seen in MM patients, especially among patients with high-risk MM. In past decades, targeted immunotherapy with monoclonal antibodies (mAbs) emerged as a major new treatment modality that offered great benefits for MM patients . Different approaches, aimed at finding potential mAbbased therapeutics for this disease including identification of alternative, or novel, target antigens , conjugation of mAbs with classic or novel drugs , and generation of chimeric antigen receptor T cells with specific mAbs , have been developed by scientists. Recently, our group has generated the mAbs that work directly against human β2-microglobulin (β2M) both in vitro and in the mouse experiments, and has demonstrated that β2M is a potential target for MM treatment .
Monoclonal, Antibodies, Neoplasm, Immunotherapy, Multiple myeloma, Monoclonal, Antibodies, Neoplasm, Immunotherapy, Multiple myeloma